sitagliptin + atorvastatin

Sitagliptin + atorvastatin is a combination therapy comprising two small molecule pharmaceuticals: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used primarily to improve glycemic control in type 2 diabetes (T2DM), and atorvastatin, an HMG-CoA reductase inhibitor (statin) used to reduce LDL cholesterol and cardiovascular risk. The combination has been proposed or used to address the dual needs of hyperglycemia and dyslipidemia in T2DM, with evidence suggesting additive effects on reducing cardiac inflammation and improving cardiac function in preclinical models. Sitagliptin acts by inhibiting DPP-4, thereby prolonging active incretin levels, enhancing glucose-dependent insulin secretion, and reducing glucagon concentrations. Atorvastatin lowers cholesterol by inhibiting HMG-CoA reductase, the rate-limiting step in cholesterol biosynthesis, and has additional pleiotropic effects, such as reducing inflammation and improving endothelial function. The combination may improve cardiovascular outcomes and adherence in appropriate patients[1][2][4].